Is less more? Pediatric intractable migraine and onabotulinumtoxinA treatment
2017
- 5Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage5
- Downloads3
- Abstract Views2
Poster Description
Objectives: The objective of this study was to analyze pediatric and adolescent chronic daily migraine response rates to modified doses of onabotulinumtoxinA.Background: Chronic migraine occurs in about three percent of pediatric headaches. Some children and adolescents are intractable to two or more preventive medications. OnabotulinumtoxinA, 155-200 units every three months was approved by the US Food and Drug Administration for the use of chronic migraine in adults in 2010. Data on effectiveness and tolerability in the pediatric population is very limited. Standard dosing is not established for children.Methods: A retrospective chart review of forty-four patients" between 11 and 21 years of age who had 15 or more headache days a month and had been intractable to at least two different prevention medication treatments for chronic daily headache prior to receiving OnabotulinumtoxinA . There were 35 female patients and 9 male patients. Those who received onabotulinumtoxinA for treatment of chronic migraine in a pediatric headache center from February of 2014 to March of 2016 were analyzed. OnabotulinumtoxinA is offered to any pediatric or adolescent patient coming to the clinic for chronic migraine if they fail two or more preventive medications. Dosing was based on location of pain and tolerance of the procedure. Injection sites were outlined based on adult standard dosing suggestions. The review analyzed age, sex, diagnosis, location of pain reported, doses of onabotulinumtoxinA tried, quantity of injection sets, and response to treatment.Results: Seventy percent of this population decreased their headache frequency and/or intensity by at least fifty percent. Forty-eight percent had less than two headaches a month. Ninety four percent of those that responded positively did so with less than one hundred and ten units of onabotulinumtoxinA.Conclusions: This suggests that "less is more" in the pediatric and adolescent dosing of onabotulinumtoxinA for treatment of chronic daily migraine.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know